Skip to main content

Table 1 Analyses of HMA combinations with AraC on BCP-ALL cells

From: Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

 

Drug combination effect

AZA + AraC

AZA + AraC (24 h)

AraC + AZA (24 h)

DEC + AraC

DEC + AraC (24 h)

AraC + DEC (24 h)

SEM

Metabolism

0.095

0.045

0.004

0.022

− 0.039

− 0.077

Proliferation

0.064

0.006

0.001

0.017

− 0.048

0.041

RS4;11

Metabolism

0.076

− 0.055

− 0.018

0.128

− 0.032

− 0.043

Proliferation

0.016

0.044

− 0.003

0.000

0.025

0.076

  1. Drug combination effect: difference between the observed and the expected inhibition (E) of combined treatment. E is calculated as follows: E = (A + B) − (A*B); A is inhibition effect of drug A; B inhibition effect of drug B values > 0: synergistic, values < 0: antagonistic
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us